AR and posterior cortical atrophy: In both, fusion negative and positive PCa, NOTCH can foster therapy resistance to the AR inhibitor enzalutamide or to docetaxel, and NOTCH suppression enhances the efficacy of androgen deprivation therapy [20,21].